Abstracts tagged "Bone density"

Abstract Number: 1257 • 2018 ACR/ARHP Annual Meeting
Simple and Cost-Effective Intervention Doubled the Rate of Osteoporosis Screening in High Risk Rheumatology Patients
Mosaab Mohameden¹, Victoria Malkhasyan², Adam Shurbaji¹ and Candice Yuvienco³, ¹Internal Medicine, University of California San Francisco - Fresno Medical Education Program, Fresno, CA, ²University of California San Francisco - Fresno Medical Education Program, Fresno, CA, ³Internal Medicine, Division of Rheumatology Director, University of California San Francisco - Fresno Medical Education Program, Division of Rheumatology Director, Fresno, CA
Background/Purpose: Osteoporosis is a common bone disorder that places patients at risk of pathologic fractures. Osteoporotic fractures can be devastating and associated with significant morbidity,…
Abstract Number: 2808 • 2018 ACR/ARHP Annual Meeting
T-Score As an Indicator of Fracture Risk on Therapy: Evidence from Romosozumab Vs Alendronate Treatment in the Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk Trial
Felicia Cosman¹, E. Michael Lewiecki², Peter R Ebeling³, Eric Hesse⁴, Nicola Napoli⁵, Daria B Crittenden⁶, Maria Rojeski⁶, Wenjing Yang⁶, Cesar Libanati⁷ and Serge Ferrari⁸, ¹Columbia University, New York, NY, ²New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ³Monash University, Melbourne, Australia, ⁴University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁵Campus Bio-Medico University of Rome, Rome, Italy, ⁶Amgen Inc., Thousand Oaks, CA, ⁷UCB Pharma, Brussels, Belgium, ⁸Geneva University Hospital, Geneva, Switzerland
Background/Purpose: BMD is a strong predictor of fracture risk in untreated patients. Recent evidence suggests that BMD achieved during treatment also reflects fracture risk; thus,…
Abstract Number: 1620 • 2018 ACR/ARHP Annual Meeting
Lateral DXA More Effective in Detecting Osteoporosis Than Conventional DXA in Axial Spondyloarthropathy
Gillian Fitzgerald^1,2, Jason Wyse³, Tochukwu Anachebe⁴, Ronan Mullan⁵, David Kane⁶, Kevin McCarroll⁷ and Finbar O' Shea², ¹School of Medicine, Trinity College Dublin, Dublin 2, Ireland, ²Rheumatology, St. James's Hospital, Dublin 8, Ireland, ³School of Computer Science and Statistics, Trinity College Dublin, Dublin 2, Ireland, ⁴Department of Rheumatology, St. James's Hospital, Dublin 8, Ireland, ⁵Department of Rheumatology,, Tallaght Hospital, Dublin, Ireland, ⁶Department of Rheumatology, Tallaght Hospital, TCD, Dublin 24, Ireland, ⁷Department of Medicine for the Elderly, St. James's Hospital, Dublin 8, Ireland
Background/Purpose: The severe consequences of osteoporosis in the general population are well outlined. In axial spondyloarthropathy (axSpA), osteoproliferation of the spine means posterioanterior (PA) dual-energy…
Abstract Number: 2810 • 2018 ACR/ARHP Annual Meeting
Fracture and Bone Mineral Density Response By Baseline Risk in Patients Treated with Abaloparatide Followed By Alendronate
Benjamin Leder¹, Carol Zapalowski², Ming-Yi Hu³ and Gary Hattersley², ¹Endocrine, Harvard Medical School, Boston, MA, ²Radius Health, Inc., Waltham, MA, ³Biometrics, Radius Health, Inc., Waltham, MA
Background/Purpose: Abaloparatide (ABL) is an anabolic PTHrP analog approved to treat postmenopausal women with osteoporosis at high risk of fracture. In the ACTIVE Phase 3…
Abstract Number: 1731 • 2018 ACR/ARHP Annual Meeting
Vertebral Fracture Prevalence and Measurement of the Scanographic Bone Attenuation Coefficient on CT-Scan in 70 Patients with Systemic Scleroderma
Marine FAUNY¹, Elodie BAUER², Eliane ALBUISSON³, Julia Perrier-Cornet¹, Joelle DEIBENER⁴, Francois CHABOT⁵, Damien MANDRY⁶, Olivier HUTTIN⁷, Isabelle Chary-Valckenaere⁸ and Damien Loeuille², ¹Rheumatology, University Hospital of Nancy, VANDOEUVRE LES NANCY, France, ²Rheumatology, University Hospital of Nancy, NANCY, France, ³University Hospital of Nancy, Nancy, France, ⁴Internal Medicine, University Hospital of Nancy, NANCY, France, ⁵Pneumology, University Hospital of Nancy, NANCY, France, ⁶Radiology, University Hospital of Nancy, NANCY, France, ⁷Cardiology, University Hospital of Nancy, NANCY, France, ⁸Rheumatology, CHRU Nancy, Vandoeuvres les Nancy, France
Background/Purpose: Osteoporosis screening is not systematic in sclerodermic patients but some studies demonstrated a similar risk between rheumatoid arthritis and systemic scleroderma [1,2,3]. Thoracic and/or…
Abstract Number: 2811 • 2018 ACR/ARHP Annual Meeting
Abaloparatide Effect on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis Aged 80 Years or Older
Susan L. Greenspan¹, Lorraine A Fitzpatrick², Bruce Mitlak², Yamei Wang², Nicholas C. Harvey³, Chad Deal⁴, Felicia Cosman⁵ and Michael McClung⁶, ¹Medicine, University of Pittsburgh, Pittsburgh, PA, ²Radius Health, Inc., Waltham, MA, ³MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom, ⁴Cleveland Clinic, Shaker Heights, OH, ⁵Columbia University College of Physicians and Surgeons, New York, NY, ⁶Oregon Osteoporosis Center, Portland, OR
Background/Purpose: The risk of fracture increases with increasing age. Thus, it is important to understand efficacy and safety of osteoporosis treatments in elderly patients. In…
Abstract Number: 2299 • 2018 ACR/ARHP Annual Meeting
Subgroup Analysis of the Effect of Denosumab Compared with Risedronate on Percentage Change in Lumbar Spine Bone Mineral Density at 24 Months in Glucocorticoid-Treated Individuals
Kenneth Saag¹, Nicola Pannacciulli², Piet Geusens³, Jonathan D. Adachi⁴, Eric Lespessailles⁵, Jorge Malouf⁶, Bente Langdahl⁷, Peter W. Butler², Xiang Yin² and Willem F. Lems⁸, ¹University of Alabama, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³Maastricht University, Maastricht, Netherlands, ⁴McMaster University, Hamilton, ON, Canada, ⁵University Hospital Orleans, Orleans, France, ⁶Hospital San Pablo, Barcelona, Spain, ⁷Aarhus University, Aarhus, Denmark, ⁸VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: We previously demonstrated that denosumab increased lumbar spine and total hip bone mineral density (BMD) significantly more than risedronate at 12 and 24 months…
Abstract Number: 2300 • 2018 ACR/ARHP Annual Meeting
Compliance with Screening and Supplementation Guidelines for Glucocorticoid-Induced Osteoporosis, How Bad Did We Do This Time?
John Zawidniak¹ and John Waterman², ¹Rheumatology, University of Connecticut, Farmington, CT, ²Rheumatology, Connecticut VA Healthcare System, Newington, CT
Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is a well-established and well-studied phenomenon that is a sequela of the treatment of many inflammatory diseases. Many studies over the…
Abstract Number: 2302 • 2018 ACR/ARHP Annual Meeting
Forearm Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis
Nelson B. Watts¹, Robin K. Dore², Sanford Baim³, Gary Hattersley⁴, Greg Williams⁵, Yamei Wang⁴, Tamara D. Rozental⁶ and Meryl S. LeBoff⁷, ¹Mercy Health Osteoporosis and Bone Health Services, Cincinnati, OH, ²Univ of California, Los Angeles, CA, ³Rush Medical College, Chicago, IL, ⁴Radius Health, Inc., Waltham, MA, ⁵Clinical Development, Radius Health, Inc., Waltham, MA, ⁶Beth Israel Deaconess Medical Center, Boston, MA, ⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: Wrist fractures are the most common fracture of the upper extremity and increase subsequent fracture risk in women with postmenopausal osteoporosis. Most wrist fractures…
Abstract Number: 2303 • 2018 ACR/ARHP Annual Meeting
Response Rates for Hip, Femoral Neck, and Lumbar Spine Bone Mineral Density in Patients Treated with Abaloparatide Followed By Alendronate
Chad Deal¹, Bruce Mitlak², Yamei Wang², Lorraine A Fitzpatrick² and Paul D Miller³, ¹Cleveland Clinic, Shaker Heights, OH, ²Radius Health, Inc., Waltham, MA, ³Colorado Center for Bone Research, Lakewood, CO
Background/Purpose: Abaloparatide (ABL) is a selective activator of the PTH1 receptor signaling pathway that stimulates bone formation. In the ACTIVE Phase 3 study, ABL significantly…
Abstract Number: 2309 • 2018 ACR/ARHP Annual Meeting
Implementation of a Primary Prevention, Population-Based Virtual Osteoporosis Clinic Dramatically Increases the Number of Rural Veterans Receiving Osteoporosis Screening and Treatment
Karla L. Miller¹, Shardool Patel², Grant W. Cannon³ and Zachary L. Anderson², ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Salt Lake City VA Medical Center, Salt Lake City, UT, ³Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT
Background/Purpose: The delivery of osteoporosis services is sub-optimal nationally and throughout the Veterans Affairs (VA) healthcare system and particularly poor for rural Veterans. To meet…
Abstract Number: 2312 • 2018 ACR/ARHP Annual Meeting
Spontaneous Vertebral Fractures after Denosumab Discontinuation
Helena Florez¹, Julio Ramírez², Ana Monegal¹, Núria Guañabens¹ and Pilar Peris¹, ¹Department of Rheumatology, Hospital Clinic, University of Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clínic de Barcelona, Barcelona, Spain
Spontaneous Vertebral Fractures after Denosumab Discontinuation.H. Florez, J. Ramírez, A. Monegal, N. Guañabens, P. Peris. Department of Rheumatology. Hospital Clinic, University of Barcelona. Background/Purpose: Denosumab…
Abstract Number: 2315 • 2018 ACR/ARHP Annual Meeting
Opportunistic Screening for Osteoporosis Using Thoraco-Abdomino-Pelvic Computed Tomography Assessing the Vertebral Density in Rheumatoid Arthritis Patients
Julia Perrier-Cornet¹, Abdou Yacoubou OMOUROU², Marine FAUNY¹, Damien Loeuille³ and Isabelle Chary-Valckenaere⁴, ¹Rheumatology, University Hospital of Nancy, VANDOEUVRE LES NANCY, France, ²Inserm, CIC-1433 Clinical Epidemiology, University Hospital of Nancy, VANDOEUVRE LES NANCY, France, ³Rheumatology, University Hospital of Nancy, NANCY, France, ⁴Rheumatology, CHRU Nancy, Vandoeuvres les Nancy, France
Background/Purpose: Screening for osteoporosis is crucial in rheumatoid arthritis (RA) patients. The aim of this study was to assess the value of thoraco-abdomino-pelvic CT-derived bone…
Abstract Number: 2322 • 2018 ACR/ARHP Annual Meeting
Intervals of Bone Mineral Density Measurement during Treatment for Osteoporosis in Patients with Rheumatoid Arthritis
Seung Yun Lee¹, Seong Ryul Kwon¹, Mie Jin Lim², Kyong-Hee Jung³ and Won Park⁴, ¹Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, Korea, Republic of (South), ²Division of Rheumatology, Departments of Internal Medicine, Inha University Hospital, Incheon, Korea, Republic of (South), ³Rheumatology, Inha University Hospital, Incheon, Korea, Republic of (South), ⁴Medicine/Rheumatology, Inha University Hospital, Incheon, Korea, Republic of (South)
Background/Purpose: There is controversy about the intervals of retesting bone mineral density (BMD) in patients treated for osteoporosis. The objective of this study is to…
Abstract Number: 318 • 2017 ACR/ARHP Annual Meeting
A Randomized Alendronate-Controlled Trial of Romosozumab: Results of the Phase 3 Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk
Kenneth Saag¹, Jeffrey Petersen², Maria Luisa Brandi³, Andrew Karaplis⁴, Mattias Lorentzon⁵, Thierry Thomas⁶, Judy Maddox², Michelle Fan², Paul D. Meisner⁷ and Andreas Grauer², ¹University of Alabama, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³University of Florence, Florence, Italy, ⁴McGill University, Montreal, QC, Canada, ⁵University of Gothenburg and Sahlgrenska University Hospital, Mölndal, Sweden, ⁶CHU de Saint-Étienne, Saint-Étienne, France, ⁷UCB Pharma, Brussels, Belgium
Background/Purpose: The bone forming agent romosozumab (Romo) was previously shown to reduce vertebral and clinical fractures in postmenopausal women with osteoporosis. Here we report the…

« Previous Page
1
…
5
6
7
8
9
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].